Gene Techno Science Signs an Agreement with Kishi Kasei to Co-Develop Biosimilar of Aflibercept

Shots:

• GTS and Kishi Kasei will jointly develop biosimilar of Aflibercept and will form a manufacturing process for the drug substance utilizing high-yield protein-producing cell lines, which were jointly developed by GTS and Fuso Pharmaceutical
• The collaboration focusses to secure a future revenue base via commercialization of biosimilar of Aflibercept and to gain market share in ophthalmologic diseases
• The companies will partner with others to jointly promote drug development, non-clinical studies, clinical studies, manufacturing and approvals, sales, etc. and create a business structure for commercialization of the product

Click here to­ read full press release/ article | Ref: GTS | Image: Kabu Fx Trends